2,3,4,5-Tetrahydro-7-methyl-1H-2-benzazepin | 40584-14-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 2,3,4,5-Tetrahydro-7-methyl-1H-2-benzazepin
• 英文别名: 7-methyl-2,3,4,5-tetrahydro-1H-benzo[c]azepine；7-Methyl-2,3,4,5-tetrahydro-1H-benzo[c]azepine；7-methyl-2,3,4,5-tetrahydro-1H-2-benzazepine
• CAS: 40584-14-3
• 化学式: C₁₁H₁₅N
• 分子量: 161.247
• InChiKey: MNYTVIWJLQZDJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• PYRIDOPYRIMIDINONE INHIBITORS OF KINASES
  申请人：AbbVie Inc.

  公开号：US20130225589A1

  公开（公告）日：2013-08-29

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R 1 , R 2 , R 3 , R 4 , and B are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.

  本发明涉及式(I)化合物或药理可接受的盐，其中R1、R2、R3、R4和B在描述中定义。本发明还涉及包含所述化合物的组合物，这些化合物可用于抑制诸如wee-1的激酶，以及治疗诸如癌症疾病的方法。
• [EN] AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS<br/>[FR] DÉRIVÉS AZA-INDOLIQUES UTILISÉS COMME INHIBITEURS DE RHO-KINASE
  申请人：CHIESI FARM SPA

  公开号：WO2019238628A1

  公开（公告）日：2019-12-19

  The invention relates to compounds of formula (I) inhibiting Rho Kinase that are azaindole derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

  该发明涉及抑制Rho激酶的式(I)化合物，这些化合物是吡唑吲哚衍生物，制备这类化合物的方法，含有它们的药物组合物以及它们的治疗用途。特别是该发明的化合物可能在治疗与ROCK酶机制相关的许多疾病中有用，如包括哮喘、慢性阻塞性肺病（COPD）、特发性肺纤维化（IPF）和肺动脉高压（PAH）在内的肺部疾病。
• [EN] SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF<br/>[FR] ACIDES HYDROXAMIQUES SUBSTITUÉS ET LEURS UTILISATIONS
  申请人：MILLENNIUM PHARM INC

  公开号：WO2010151318A1

  公开（公告）日：2010-12-29

  This invention provides compounds of formula (/): wherein R1, R2, G, m, n, p and q have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

  这项发明提供了以下式子的化合物：其中R1、R2、G、m、n、p和q的取值如规范中所述，这些化合物可用作HDAC6的抑制剂。该发明还提供了包括该发明化合物的药物组合物，以及使用这些组合物治疗增殖性、炎症性、感染性、神经系统或心血管疾病或紊乱的方法。
• PYRIDAZINO[4,5-D]PYRIMIDIN-5(6H)-ONE INHIBITORS OF KINASES
  申请人：AbbVie Inc.

  公开号：US20140296220A1

  公开（公告）日：2014-10-02

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein B, R 1 , R 2 , R 4 , and m are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.

  本发明涉及化合物(I)或药物可接受的盐，其中B、R1、R2、R4和m在说明中有定义。本发明还涉及含有所述化合物的组合物，其对抑制激酶如wee-1有用，以及治疗癌症等疾病的方法。
• Azaindole derivatives as Rho-kinase inhibitors
  申请人：CHIESI FARMACEUTICI S.p.A.

  公开号：US11332468B2

  公开（公告）日：2022-05-17

  The invention relates to compounds of formula I inhibiting Rho Kinase that are tyrosine analogues derivatives, processes of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

  本发明涉及抑制 Rho 激酶的酪氨酸类似物衍生物的式 I 化合物、制备此类化合物的工艺、含有此类化合物的药物组合物及其治疗用途。特别是本发明的化合物可用于治疗许多与 ROCK 酶机制相关的疾病，如肺部疾病，包括哮喘、慢性阻塞性肺病 (COPD)、特发性肺纤维化 (IPF) 和肺动脉高压 (PAH)。